Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2

摘要

A Pathway analysis of proteins enriched in HGSOCs (n = 10) compared with FTs (n = 10) based on proteomics data. Samples were collected from Qilu Hospital, Shandong University. B Heat map showing expression levels of splicing factors upregulated in HGSOCs (n = 6) compared with FTs (n = 6) based on transcriptome microarray results ({"type":"entrez-geo","attrs":{"text":"GSE135886","term_id":"135886"}}GSE135886). Samples were collected from Qilu Hospital, Shandong University. C, D USP39 mRNA expression was compared between HGSOCs and normal tissues from the TCGA cohort (C) and our cohort (D). E Representative images of immunohistochemical (IHC) staining of USP39 in our tissue microarray (containing 149 samples of HGSOCs and 41 samples of FTs collected from Qilu Hospital, Shandong University). F Statistical analysis of USP39 expression from IHC staining of our tissue microarray. High and low expression indicate the final score of each sample determined by two pathologists based on the intensity and extent of staining across the tissue microarray section. HGSOC patients were dichotomized into low (Score ≤7) and high (Score >7) USP39 protein expression groups based on IHC staining score. G Kaplan–Meier analysis of the correlation between USP39 expression and clinical prognosis based on data from our tissue microarray. H Kaplan–Meier analysis of the effect of USP39 mRNA expression on the overall survival and progression-free survival of ovarian cancer patients based on an online cohort from Kaplan–Meier Plotter (http://kmplot.com/). The high and low expression groups were separated based on the best cutoff. P value was obtained by Student’s t-test (C, D, F) or Log-rank test (G, H). *P < 0.05, **P < 0.01, ***P < 0.001.